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 Abstract 
Metabolic reprogramming plays an important role in cancer development and 
progression and is a well-established hallmark of cancer. Despite its inherent 
complexity, cellular metabolism can be decomposed into functional modules that 
represent fundamental metabolic processes. Here we performed a pan-cancer study 
involving 9428 samples from 25 cancer types to reveal metabolic modules whose 
individual or coordinated activity predict cancer type and outcome, in turn highlighting 
novel therapeutic opportunities. Integration of gene expression levels into metabolic 
modules suggests that the activity of specific modules differs between cancers and the 
corresponding tissues of origin. Some modules may cooperate, as indicated by the 
positive correlation of their activity across a range of tumors. The activity of many 
metabolic modules was significantly associated with prognosis at a stronger magnitude 
than any of their constituent genes. Thus, modules may be classified as tumor 
suppressors and onco-modules according to their potential impact on cancer 
progression. Using this modeling framework, we also propose novel potential 
therapeutic targets that constitute alternative ways of treating cancer by inhibiting their 
reprogrammed metabolism. Collectively, this study provides an extensive resource of 
predicted cancer metabolic profiles and dependencies. 
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Introduction 
Changes in metabolism were first linked to cancer almost one century ago (1), 
particularly from the observation of enhanced aerobic glycolysis (also known as the 
Warburg effect) (2). It is well known that the common proliferative phenotype of cancer 
cells require intensive support for the biosynthesis of cellular components and 
generation of energy, which overall are accomplished by reprogramming metabolism 
(2,3). Actually, it has long been known that key signaling pathways that are altered in 
cancer are important regulators of metabolism (4). In fact, in addition to the Warburg 
effect, other alterations in the synthesis of nucleotides, amino acids and lipids (5), 
mutations in metabolic genes and accumulations of key metabolites (6) have been 
reported. Consequently, reprogramming of cellular metabolism is a recognized essential 
feature for cancer development and progression (7), and is therefore a recognized 
neoplastic hallmark (7,8). This observation, along with the discovery of the therapeutic 
potential of metabolic targets in cancer (9), has sparked a growing interest in cancer 
metabolism (3,4). Recent studies show that genes involved in metabolic pathways 
shows a remarkable heterogeneity across various cancer types (8), which suggests that 
personalized therapies are likely to be successful if the context of the intervention is 
accurately depicted. In this context, synthetic lethality, defined as combined molecular 
perturbations with a drastic effect on cell viability, but with no individual effect, offers a 
promising range of potential therapeutic interventions based on cancer metabolic 
dependencies (10). 
Despite the inherent complexity of the metabolism, various approaches based on the 
integration and modeling of functional genomic data have allowed the reconstruction of 
genome-scale metabolic networks (11). Indeed, recent studies have demonstrated that 
complex phenotypes or outcomes such as patient survival (12,13) and drug activity (14) 
are better predicted by the inferred activity of pathways, than by the activity of their 
constituent genes and/or proteins. Constraint-Based Models (CBMs), which use maps of 
metabolic networks in combination with gene activity inferred from transcriptomic 
profiles, have been applied to decipher relationships between various aspects of the 
cellular metabolism and phenotypes (15). In fact, CBMs have enabled the analysis of 
metabolism in different scenarios at an unprecedented level of detail (16). However, 
CBMs have several analytical and modeling limitations, such as the dependence of their 
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solutions on initial conditions or the sometimes unrealistic and arbitrary nature of some 
of the assumptions and difficulties of convergence on unique solutions (17)). 
Recently, realistic computational models of signal propagation have been successfully 
applied to predict complex phenotypes using estimates of signaling pathway activities 
inferred from gene expression data (13,14). In addition, such models provide important 
information about disease mechanisms and mode of action (MoA) of drugs (13). Here 
we generalize the application of this approach to describe the metabolic profiles and 
dependencies across 14 cancer types. Our study reveals common and specific metabolic 
modules that influence patient survival. We also identify metabolic dependencies based 
on targeted molecular predictions that point to novel beneficial therapeutic 
interventions.  
An interactive and intuitive web has been developed to explore the data predictions and 
perform further metabolic modeling base on users’ data and hypotheses 
(http://metabolizer.babelomics.org/).  
Material and methods 
 
Data 
 
Human samples and data processing 
RNA-seq counts for a total of 9428 samples, 8319 corresponding to cancer and 649 to 
healthy reference tissue, belonging to 25 cancer types, (see Table S1), as well as their 
subtype stratification, were downloaded from The International Cancer Genome 
Consortium (ICGC) repository (https://dcc.icgc.org/releases/release_20/Projects). The 
trimmed mean of M-values (TMM) normalization method (18) was used for gene 
expression normalization.  
Data on somatic mutation in genes from the modules was taken from the CDG cancer 
portal (https://portal.gdc.cancer.gov/files/995c0111-d90b-4140-bee7-3845436c3b42), 
Expression data on responses to drugs were taken from GSE25066, GSE50948, 
GSE5462 datasets downloaded from GEO. Probes mapping in more than one gene were 
discarded. The median value of the probes mapping on a gene was used as the 
expression value for this gene. Microarray data normalization and background 
correction was done using RMA method implemented in the affy Bioconductor package 
(https://bioconductor.org/packages/release/bioc/html/affy.html). Normalized samples 
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were log-transformed and a truncation by quantile 0.99 was applied. The COMBAT 
method (19) was used for batch effect correction. Finally, data were re-scaled between 0 
and 1.  
Clinical data 
Clinical data were available through the cBIOportal (http://www.cbioportal.org/). These 
data included individual survival information that was used for survival analysis. 
Cell line expression values and cell line survival data 
A total of 212 cell lines were used in this study (Table S2). Gene expression data were 
taken from the Cancer Cell Line encyclopedia (https://portals.broadinstitute.org/ccle/). 
Cell survival measurements after gene KD were taken from the Project Achilles 2.4.3  
(https://portals.broadinstitute.org/achilles/datasets/5/download). Survival validation data 
were taken from the new release 2.20.2 of the project Achilles 
(https://portals.broadinstitute.org/achilles/datasets/15/download). 
 
Modelling framework 
 
A model of the activity of a pathway requires of: i) a description of the current map of 
relationships between the proteins that make up the pathway and ii) a function that 
relates the activity of the pathway to those of the constituent proteins.  
Module definition 
Pathway modules (20) are used to describe the map of interactions between the proteins 
that ultimately carry out the main metabolic transformations in the cell. Pathway 
modules are modular sequential metabolic reactions that consist of conserved functional 
units of enzyme complexes and metabolic sub-pathways, representing a summary of the 
known human metabolism (20). A total of 86 modules were downloaded from the 
KEGG MODULE (http://www.genome.jp/kegg/module.html) database (Table S3).  
Since seven of them ended in more than one metabolic product, these were decomposed 
into two sub-modules, resulting in a final number of 95 modules. The modules comprise 
a total of 446 reactions and 553 genes. Specifically, the metabolic pathways were 
downloaded as KGML files and were parsed to extract detailed information about the 
metabolites, genes and reactions. Reactions and metabolites in the module are 
represented as nodes that are connected by the edges of the graph in a way that 
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describes the sequence of reactions that transform simple metabolites into complex 
metabolites, or vice versa (see Figure S1). 
Module activity estimation 
Once a module has been formally described by a graph, its activity level can be 
described as a function of the activities of all the reaction nodes (composed of one or 
several isoenzymes or enzymatic complexes (21)) and the presence of all the 
intermediate metabolites. Reaction node activity can be estimated from the presence of 
the corresponding proteins. Since direct measurements of protein levels are commonly 
difficult to obtain, the presence of the corresponding mRNA expression level within the 
context of the module is widely used as a proxy (13,22,23). Normalized gene expression 
values are used for this purpose, as explained above. To estimate the potential activity 
of the reaction node two scenarios are considered (24): isoenzymes, where the activity is 
produced if at least one of them is present (ExpressionIsoenzyme1 OR ExpressionIsoenzyme2 
OR …) and enzymatic complexes, where the activity occurs only if all the enzymes are 
present (ExpressionEnzymeA AND ExpressionEnzymeB AND …). For example, in Figure 
S1, the last reaction transforming isocitrate into 2-oxoglutarate is catalysed by either an 
enzymatic complex or two alternative isoenzymes, represented as “(R01899 AND 
R00268) OR R00267 OR R00709”, which may be estimated from the normalized gene 
expression values of the mRNAs corresponding to proteins R01899, R00268, R00267 
and R00709 as: 
𝑛 = 𝑚𝑎𝑥{𝑚𝑖𝑛{𝐸𝑅01899, 𝐸𝑅00268}, 𝐸𝑅00267, 𝐸00709} 
where n is the activity of the node and Ep is the 90
th
 percentile of normalized expression 
of the gene corresponding to the enzyme p. This approach is very similar to computing 
the Gene-Protein-Reaction (GPR) rules in metabolic networks (24). It is worth noting 
that some enzymes can participate in more than one node (even in different modules), 
and thereby contribute to different reactions. 
As in the case of protein activities, metabolite measurements are typically not 
simultaneously available with gene expression measurements and therefore the 
metabolite nodes have been excluded here from the calculations (equivalent to setting 
all their values to 1, assuming that all of them are present). However, if metabolite 
measurements were available, they could easily be accommodated in this modelling 
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framework by normalising them and using the corresponding values in the graph. Once 
node activities have been estimated, the contribution of each node to the integrity of the 
chain of reactions leading from simple to complex metabolites can be computed using a 
recursive method. Starting with a value of 1, in the node corresponding to the simplest 
metabolite, the activity of the subsequent nodes is calculated by the formula: 
𝑆𝑖 = 𝑛𝑖 ∙ (1 − ∏(1 − 𝑠𝑎)
𝑠𝑎∈𝐴𝑖
) 
where ni is the activity of the current node n, A is the total number of edges arriving at 
the node that account for the flux of metabolites produced in other nodes with activity 
values sa, and Si is the flux of the current reaction node. 
The net value of integrity of the whole circuit of reactions represented in the module is 
summarized by the value of activity propagated until the last node that carries out the 
last reaction that produces the resulting metabolite of the chain of reactions. 
Differential module activity estimation 
Activity values for the modules calculated in this way are dimensionless values that, 
like normalized gene expression values, make sense in a comparative context that 
makes it possible to decide whether the activity of a given module exhibits a significant 
variation or not. The Wilcoxon test is used to assess the significance of the observed 
changes of module activity when samples of two conditions are compared.  
Since many modules were simultaneously tested, the popular FDR method (25) was 
used to correct for multiple testing effects. 
Survival analysis 
 
Kaplan-Meier (K-M) curves were used to relate module activity to patient survival in 
the different cancers. The value of the activity estimated for each module in each 
individual was used to assess its relationship with individual patient survival. 
Calculations were carried out using the function survdiff in the survival R package 
(https://cran.r-project.org/web/packages/survival/).  
Cox regression analysis (26) was used to relate combined module activity to survival in 
the different cancers. Calculations were carried out using the coxph function in the 
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survival R package (https://cran.r-project.org/web/packages/survival/). A stepwise 
algorithm implemented in the step function of the stats R package 
(https://stat.ethz.ch/R-manual/R-devel/library/stats/html/step.html), was used to add or 
remove modules according to the significance of their contributions to explain survival 
in the multiple regression model. The step function uses the Akaike Information 
Criterion (AIC) to select the best model by iteratively adding and removing variables. 
Finally, the method yields a list of modules whose combination is significantly related 
to survival. Adjustment for multiple testing was made by the FDR method (25). For 
patient stratification based on predicted module activity, high and low module activity 
groups were defined using the 80% and 20% percentiles, respectively. 
Module essentiality 
 
Simulation of the effect of gene knock-downs on module activity 
Given a set of gene expression values (wt expression), the activity of the modules was 
estimated as described above (wt activity). Then, the knocked down gene(s) expression 
value(s) were set to 0.001 (KD expression) and the activity of the modules was 
recalculated again (KD activity). The log-fold-change in module activities was then 
calculated from the comparison of KD and wt module activity profiles as  
Log-fold-change = log(KD module activity) - log(wt module activity) 
Relationship between module activity and cell survival 
To estimate module activity essentiality cell lines were grouped by cancer type. For 
each cancer type the impact of gene KDs on the activity of the modules was calculated 
as described above. Then, a Spearman correlation coefficient between log-fold-change 
values and cell survival, as described in the Project Achilles was calculated. Lower 
Achilles scores indicate higher mortality and, consequently, essentiality of the KD gene. 
Positive correlations indicate essentiality in module activity (the less activity the lower 
the Achilles index) in this particular cancer type.  
 
Validation of the essentiality predictions 
 
Independent dataset validation 
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In order to check the correspondences between gene expression data and protein 
expression data we have used the reverse phase protein array (RPPA) assays available 
in the ICGC repository. 
Data on cancer dependencies, which include estimates of cell viabilities after gene KD, 
from the Project Achilles 2.20.2  was used to check the validity of the predictions made 
with the Project Achilles 2.4.3 (TableS2 and references therein). It was expected that the 
inhibition of an onco-module would reduce the viability of cancer cells. Conversely, the 
inhibition of a tumor suppressor module should result in greater cell survival. In order to 
detect these increases or decreases, the Project Achilles 2.20.2 cell viability scores 
observed in the cell line in which an effect of KD on cell survival was predicted were 
compared with the scores reported for the other cell lines (background score). Increases 
or decreases in the mean values were taken as evidences of predicted effects on cell 
viability. 
 
Experimental validation 
The shRNAs targeting UPB1 were purchased from the MISSION library (Sigma 
Aldrich), catalog SHCLNG-NM_016327. Lentivirus was produced and transduced 
following standard protocols and cell cultures were selected with puromycin for 72 
hours before cell seeding for evaluation of proliferation/viability by methylthiazol 
tetrazolium (MTT)-based assays (Sigma-Aldrich). The data corresponds to sextuplicates 
and were replicated in different assays. UPB1 expression was detected with the Human 
Protein Atlas HPA000728 antibody (Sigma-Aldrich) and gene expression measured 
with primers 5´-TCGACCTAAACCTCTGCCAG-3’ and 5’-
TAAGCCTGCCACACTTGCTA-3’, using PPP1CA as control. 
 
Results 
Data pre-processing 
RNA-seq counts for 25 cancer types, totaling 9428 samples (Table S1) were 
downloaded from The International Cancer Genome Consortium (ICGC) repository. 
Principal component analysis (PCA) was used to detect possible batch effects. The 
results are shown by plotting samples with respect to disease status (Figure S2A and 
S2B), sequencing center (Figure S2C and S2D) and project (Figure S2E and S2F). An 
appreciable technical batch effect due to sequencing center was found (Figure S2 C) and 
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this was corrected by application of the COMBAT (19) method (Figure S2 D). Samples 
were normalized and preprocessed as explained in Methods. 
 
Concordance between gene expression, protein expression and module activity  
Since the predictions of the proposed method are based on gene expression values, data 
from protein expression measurements in reverse reverse-phase protein array (RPPA) 
were used to validate them. Excluding biochemical modifications, 13 genes encoding 
for enzymes contained in KEGG pathways were included in RPPAs; thus, 11 of these 
genes showed positive expression correlations (Spearman's rank correlation coefficients, 
p < 0.05) with their corresponding protein measures in at least one cancer type (Table 
S4A). Only two genes, GAPDH and ACACB, were negatively correlated with their 
RPPA measures in some cancer types, which is a similar proportion to that revealed by 
the analysis of genome-wide gene and protein expression profiles (27). Importantly, 
previous pan- and specific-cancer analyses have shown common and robust positive 
correlations between gene expression and RPPA measures (28). In addition, in seven of 
the ten modules including an enzyme that was measured by RPPAs, a positive 
correlation between predicted module activity and enzyme expression was found in at 
least three cancer types (Table S4B). Moreover, analysis of 201 proteins included in the 
RPPAs identified positive gene-protein expression correlations in 176 (88%) instances 
across any cancer type (Table S5). To further assess the validity of the predictions, 
metabolomic data from breast and kidney cancer were then analyzed (Table S6 and 
references therein). We used the balance between the initial and final metabolite fold-
changes as an indication of activation (relative increase in the final metabolite with 
respect to the initial one) or inactivation (relative decrease in the final metabolite with 
respect to the initial one). With the premise that both the initial and final metabolites of 
each module were measured in these studies, we found two datasets where three 
modules could be evaluated, and, for these settings, all of our five predictions proved to 
be correct (Table S6 and references therein). Therefore, the predictions from our study 
are generally transferable to the protein expression and metabolic activity levels. 
 
Pan-cancer metabolic activity profiles 
For this differential module activity analysis we used 14 cancer types in which at least a 
5% of healthy reference samples were available (totaling 6299 cancer samples and 687 
healthy samples). For each cancer type, the activity of the modules was calculated for 
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all tumors and for all healthy tissue samples as described in Methods. Briefly, gene 
expression profiles were converted into metabolic module activity profiles by applying 
a formula that takes into account the chain of metabolic reactions required to complete 
the transformation of simple into complex metabolites in each module. Next, the 
Wilcoxon test was used to assess differences between conditions. Figure 1 shows the 
significant activations and deactivations of modules in tumors with respect to the 
corresponding healthy tissue.  
 
Subtype-specific metabolic profiles 
Since ICGC provides subtype annotations for six cancer types, it is straightforward to 
produce a similar analysis of differential module activity at the subtype level. For each 
of the six cancer types analyzed, Table S7 recapitulates the modules that present 
significant differential activity in the subtypes of BLCA (Table S7A and S7B), BRCA 
(Table S7C), COAD (Table S7D and S7E), LUAD (Table S7F), PRAD (Table S7G) 
and STAD (Table S7H) with respect to the corresponding normal tissue (in red) and 
those whose differential activity is specifically detected only in one of the subtypes (in 
blue). In some cancer subtypes no subtype-specific activities were detected. In many 
cases this was due to the small number of samples available.  
 
Metabolic modules may be altered by oncogenic mutations 
Many cancer drivers are known to promote metabolic reprogramming in cancer. To test 
our predictions in this context, we analyzed the impact of relatively frequent oncogenic 
mutations in well-established drivers linked to metabolic reprogramming; AKT1 and 
PIK3CA in BRCA, and IDH1 in GBM (Table S8A and S8B). Consistent with a major 
role linked to metabolism, mutations in PIK3CA caused significant changes in the 
predicted values of many metabolic modules, with coherent changes in seven of the 
modules also being significantly altered by AKT1 mutations (Table S8C). Among the 
altered modules in PIK3CA mutants, some of the findings were consistent with current 
knowledge. The largest predicted metabolic activation in PIK3CA mutants is found to 
be the M00027 module of GABA shunt (end metabolite succinate), which is consistent 
with data of reprogrammed glutamine metabolism in this setting (Table S8C and 
references therein). In contrast, the activity of the M00034_1 module of methionine 
salvage is predicted to be higher in PIK3CA wild-type tumors, but interestingly this 
pathway becomes activated as a mechanism of resistance to PI3K inhibitors (Table S8C 
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and references therein). The IDH1 mutations in GBM caused fewer module alterations, 
probably in part because only seven mutated samples were included in the analysis. 
Nonetheless, the largest impact upon IDH1 mutations is predicted to be activation of 
proline biosynthesis (M00015), which links to metabolites downstream of IDH1 activity 
(Table 5A and references therein). Another predicted effect was the downregulation of 
glycosphingolipid biosynthesis (M00071), which is consistent with the major demand of 
citrate towards the substrate of the reaction catalyzed by IDH1. In turn, the major 
activation corresponds to components down-stream of its activity that is related to 
proline biosynthesis (M00015) (Table S8C). Thus, the predictions from this study may 
also support the identification of specific, cancer driver-linked, metabolic 
reprogramming and/or vulnerabilities. 
 
Cooperation between metabolic modules 
Metabolic modules do not function in isolation, but rather display highly correlated 
(positive or negative) patterns of activity that influence cancer development and/or 
progression (8,23). However, how these correlations vary from normal tissue to cancer 
is poorly understood. Our results document a variable proportion of modules, ranging 
from 5.3% (in LIHC) to 26.9% (in READ), that are significantly positively correlated in 
normal tissue but not in the corresponding tumor. This proportion is smaller for 
negative correlations, ranging from 1.1% (in LUSC) to 10.6% (in BLCA). 10-35% of 
the activity of metabolic modules is uncoupled when normal and cancer metabolic 
activities are compared (Figure 2). Figure S3 represents in detail the modules whose 
activities are correlated in normal and/or cancer tissue and those in which the 
significance or direction of the correlation change.  
 
Modules associated with cancer outcome  
Modules differentially activated between cancer and the corresponding normal tissue 
may highlight metabolic processes that are required for cancer development and/or 
progression. The availability of patient survival data in 21 cancer types (See Table S1) 
allows the identification of modules in which changes in activity are significantly 
associated with the progression of each cancer type.  
Table S9 portrays the modules whose change in activity is significantly associated with 
poorer patient survival in at least one cancer type. Since the number of deceased 
patients and, in general, data on mortality follow-ups is limited in the ICGC repository, 
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significant results were obtained for only a few modules. In particular, kidney (KIRC), 
liver (LIHC) and glioma (LGG) cancer types featured a remarkable number of modules 
influencing cancer outcome.  
Moreover, following from the observation of correlated modules, the impact on survival 
may be further determined by combinations of their metabolic activities. Thus, we 
applied Cox multiple regression analysis (26) to find the combination of module 
activities that best accounted for patient survival. Table S10 shows the combinations of 
module activities significantly related to survival in various cancer types.  
Previous results have shown that predicted activities of single or combined metabolic 
modules are associated with differences in cancer outcome, further emphasizing their 
fundamental role in cancer progression. In addition, we observed that the magnitude of 
their effect on survival was greater in some instances than for any of the individual 
activities of the genes that comprise a given module, which provides additional 
evidence that modules are real entities that contribute as whole units to cell functioning 
(see Table S11).  
 
Modules associated with differential cancer therapeutic responses 
Since we observed that metabolic activities influence cancer progression, they may also 
modify therapeutic responses. To examine this possibility, we analyzed gene expression 
data from three breast cancer studies involving different therapeutic settings: response 
to neoadjuvant taxane-anthracycline chemotherapy, response to neoadjuvant herceptin 
(NOAH trial), and early response to letrozole (Table S12A and references therein). 
Several metabolic modules were identified as potential modifiers of response to 
neoadjuvant taxane-anthracycline chemotherapy, including glycolysis (M00002), which 
has been extensively linked to chemoresistance and is thought to be a target for 
impairing this process (Table S12A and references therein). The analysis of the data 
from neoadjuvant herceptin identified a single significant metabolic module, 
catecholamine biosynthesis (M00042), a process that has been linked to resistance to 
anti-HER2 therapy (Table S12B and references therein). Evaluation of the metabolic 
modules that change significantly in response to letrozole identified several candidates, 
including serine biosynthesis (M00020) and methionine degradation (M00035_1), both 
of which processes have been linked to resistance to another endocrine therapeutic 
approach, based on tamoxifen (Table S12C and references therein). Therefore, 
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metabolic alterations predicted by this study may represent novel therapeutic 
opportunities for boosting the clinical benefit of standard treatments. 
 
Essentiality and module activity 
The availability of basal gene expression data from 212 cell lines of the Cancer Cell 
Line encyclopedia, along with the release of the results of Project Achilles (Table 2 and 
references terein), which assessed the consequences of individual silencing of thousands 
of genes across many cancer cell lines, allows the influence of predicted metabolic 
module activities on cancer robustness to be evaluated. The effect of every gene 
expression KD on the activity of the corresponding module was calculated as the log-
fold-change between the estimated activity using cell line gene expression values and 
the activity estimated by assigning a very low expression value (see Methods) to the KD 
gene. Subsequently, the correlations of the log-fold-change values with the Achilles 
score, which accounts for cell viability, were calculated. Given that different cancer 
types display specific patterns of differential module activations, essentiality in modules 
is also expected to be specific to particular cancer types. Therefore, cell lines were 
grouped by cancer type to obtain the correlations between module activity and cell 
viability. Considering only significant correlations (FDR adjusted p-value < 0.05) with a 
correlation coefficient > 0.5 (or < -0.5) obtained from at least eight data points (cell 
lines x KD genes), a total of 20 modules in 12 cancer types showed significant positive 
(Table 1 and Figure 3A) or negative correlations (Table 1 and Figure 3B). 
 
Validation of the gene essentiality predictions 
We used a recently published study on cancer dependencies (Table 2 and references 
therein) that provides extra data on cell survival after massive gene KD. The 
comparison of cell survival in the cancer types predicted with respect to survival in 
cancers validated 48 of the 77 predictions (62%), along with three less conclusive 
validations, which would result in a 66% validation rate, covering 24 of the 28 modules 
predicted to affect cell viability (see Table 1 and, in more detail Table S13). This is an 
excellent proportion of validations, especially if we consider that the method used for 
validation can fail to detect real KD effects when the KD also markedly affects 
background survival.  
Actually, independent experiments can confirm inconclusive validations of predicted 
inhibitions of essential modules. An interesting example is the small molecule, CBR 
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5884, which inhibits PHGDH causing selective toxicity in breast cancer cell lines by 
inhibiting serine biosynthesis (29), as predicted (see Table 1 and Table S13).  
Finally, to further validate of our predictions (Table 1), the impairment of cell 
proliferation upon depletion of UPB1 gene expression was assessed in two models of 
gastric cancer (AGS and MKN45 cell lines). This gene encodes an enzyme (β-
ureidopropionase) that catalyzes the final step in the pyrimidine degradation pathway, 
which in turn is required for epithelial-mesenchymal transition (30). Thus, two short 
hairpin shRNA sequences directed to UPB1 caused a significant decrease in 
proliferation of the two gastric cancer cell lines (AGS and MKN45), as predicted by the 
model. Conversely, the inhibition in a colon adenocarcinoma cell line (SW480), 
predicted as non-essential by our model did not result in a significant difference in 
growing (Figure 4), providing a negative control validation. Although additional 
experiments may be warranted to confirm cancer vulnerability or resistance based on 
predicted metabolic activities, these results can be considered independent validations 
that reinforce the predictions made by the model proposed (Table 1 and Table S13).  
 
Therapeutic targeting of metabolic modules 
Onco-modules are effective candidates for treating cancer (individually or in 
combinations), but interventions that activate some tumor suppressor metabolic 
modules may also offer useful therapeutic strategies. Table S14 lists 137 potential 
interventions with known drugs that are likely to affect cancer cell viability according to 
the predictions of the model proposed here.    
 
Discussion 
Although the role of metabolism in cancer has long been known (1,2), the results 
presented here provide a more detailed, mechanistic view documenting the relevance of 
specific metabolic module activities in cancer. This study is based on the integration of 
gene expression data into metabolic pathway modules and, therefore, may be limited by 
the lack of correlation between gene and protein expression, and with metabolic 
activities, in some instances; however, evaluation of RPPA data and module activity 
predictions, in accordance with independent studies (28), indicates that gene expression 
measures are generally a valuable proxy for protein expression and activities.  
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As expected, the production of nucleotides and their precursors (CDP and GTP) shows 
recurrent significant activation in all cancer types when compared with the 
corresponding reference tissues (Figure 1). Other pervasively activated modules include 
well-known cancer metabolic dependencies, like cholesterol biosynthesis (M00101), 
which is consistent with its essential role in cell membranes and as a precursor of 
steroid hormones (31), and proline biosynthesis (M00015), which is essential in many 
carcinogenesis settings (32). In addition, the predicted overexpression of L-
cystathionine and L-cysteine across many cancer types may reflect a defect in S-
adenosyl-L-methionine, which in turn is consistent with common DNA 
hypomethylation in cancer cells (33). On the other hand, this study reveals metabolites 
whose production is significantly reduced in several cancers types. For example, the 
well-known Warburg effect, i. e., the preference of cancer cells for anaerobic over 
aerobic metabolism is apparent in modules such as Citrate cycle, second carbon 
oxidation (M00011). It is also known that many human tumors do not express ASS1 
(34), one of the key enzymes of the Urea cycle (M00029) module, which is 
systematically downregulated in almost all cancer types.  
Specific observations also support the relevance of the predicted metabolic activities. 
Examples of cancer metabolic specificities are: upregulation of leucine (M00036) and 
catecholamine metabolism (M00042) in prostate (35) and colorectal (36) cancer, 
respectively, and downregulation of glycosaminoglycan (M00058) and polyamine 
biosynthesis (M00134) in liver (37) and breast (38) cancer, respectively. In turn, this 
study highlights less explored metabolic associations, such as downregulation of the 
pentose phosphate cycle (M00004) in head and neck cancer, or accumulation of cysteine 
(M00338_1) in several cancer types, which may indicate a link to altered metabolism of 
reactive oxygen species. Collectively, the results of this study depict biologically 
relevant metabolic profiles throughout human cancer and provide many novel 
hypotheses about metabolic alterations in the disease. 
Metabolic modules are also relevant for establishing the molecular basis that 
differentiates between cancer subtypes. Table S7 provides a detailed survey of 
differential and common metabolic module activities when cancer subtypes are 
compared. Although a detailed description of the findings is beyond the scope of this 
manuscript it is worthwhile highlighting some observations, such as the significant 
specific reduction of the activity of the module C21-Steroid hormone biosynthesis, 
progesterone (M00109) in basal-like breast cancer subtype (the only non-hormone 
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dependent form of the disease) (39). Experts in specific cancer types can use Table S7 
to identify relevant subtype-specific module activities that can be exploited for 
therapeutic purposes.  
Some of the modules that display different behaviors in cancer are expected to have a 
direct effect on patient survival. In spite of the limited patient survival data in the ICGC 
repository, Table S9 demonstrates that a remarkable number of modules are associated 
with poorer patient survival. Specifically, a high level of activity of the pentose 
phosphate module was found to be significantly associated with poor survival in five 
cancer types (see Table S9 and K-M plots in Figure 5A). This observation is consistent 
with the role of this module in the biosynthesis of nucleotides and NADPH, which is 
known to play a key role in facilitating cancer cells to cope with anabolic demands and 
to fight oxidative stress (40).  
The analysis of metabolic modules reveals their role as ultimate mechanistic entities 
whose activity is related to cancer cell fate. For example, the expression of EHHADH 
has recently been associated with poor prognosis of KIRC (41), but the corresponding 
module, Malonate semialdehyde pathway (M00013) better predicts outcome (see Table 
S11).  In fact, out of the 69 metabolic modules associated with differences in survival, a 
total of 27 (40%) modules (see Table S11) showed a stronger effect (based on hazard 
ratio estimations) than any of their corresponding genes. Other modules are also 
significantly related to survival in other cancer types as LGG (Figure 5B), KIRC 
(Figure 5C) or KIRP (Figure 5D). 
Moreover, in the same way that genes are co-regulated in higher-level entities 
(metabolic modules), the activations and deactivations of metabolic modules are not an 
independent process and, in fact, proper cell functionality seems to require a high 
degree of module activity coordination. Figure 2 illustrates how only a few core 
processes originally correlated in the normal tissues maintain the correlation in all 
cancer types. An example of this concordance is the positive coordination between 
fumarate, succinyl-CoA, and urea, which indicates the expected link between the citric 
acid and urea cycles (Figure S3). Unexpectedly, some modules uncorrelated in normal 
tissue emerge as being coupled in tumors (see Figure S3). Thus, according to cancer 
metabolic demands, bile acids (e.g. cholic acid, M00104_1) is positively correlated with 
cholesterol (M00101) and triacylglycerol (M00089). In turn, the negative correlation of 
the previous metabolites with a glycosphingolipid (globoside, M00068), which is linked 
to differentiation and antigenicity (42), is lost in cancer. Similarly, cholesterol is 
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positively correlated with nucleotide sugar biosynthesis (M00554 and M00632_1), but 
another glycosphingolipid (ganglioside, M00069) is negatively correlated with this 
process only in normal tissue. Collectively, these results further highlight the 
complexity of metabolic reprogramming in cancer. 
Available data on survival of cancer cell lines after extensive KD (Table 2 and 
references therein) allowed the model to be used to relate module activity to cell 
survival in cell lines. Positive correlations between module activity and cell viability 
(see Table 1) indicate that the corresponding module may play an essential role in the 
corresponding cancer type. Therefore, they can be classified as onco-modules. Such 
constitutively active modules include common cancer dependencies, like nucleotide 
sugar biosynthesis, necessary for cell proliferation, and heparan sulfate degradation, 
necessary for extracellular matrix biosynthesis and thereby, cancer progression and 
invasion (37). Conversely, tumor suppressor modules showed negative correlations with 
cell viability possibly indicating constraints in cancer development and/or progression. 
These modules include bile acid biosynthesis (M00104), which produces metabolites 
known to induce apoptosis and inhibit cancer cell proliferation (43) (Table 1 and Figure 
3B). In addition, the study identifies modules with contrary effects depending on the 
tissue of origin, which probably indicate specific cancer dependencies. For example, 
inosine monophosphate biosynthesis is positively (bone) or negatively (prostate) 
correlated depending on whether there is also reduced or enhanced oxidative 
phosphorylation, respectively (44).  
The detection of onco-modules and tumor suppressor modules was used to suggest 
previously unidentified potentially actionable genes (Table 1), because the model 
proposed predicted an effect of their KD on the activity of the corresponding modules. 
Recently published extra data on cell survival after massive gene KD (Table 2 and 
references therein) was used to validate the predictions made, confirming these for 62% 
of the genes (48 of the 77 predictions) included in 86% of the modules (24 of the 28), 
which constitutes a high rate of validation.  
Given the level of accuracy of the predictions of the model of metabolic module 
activities the obvious subsequent step was to predict the effect of drugs, with known 
targets within modules, in order to shed light on their mechanisms of action (MoA). 
Actually, components of some metabolic modules are targeted by well-known clinical 
drugs, such as gemcitabine, which is approved for the treatment of several cancer types 
(See Table S14 and specifically DB00441 entry in DrugBank). This drug is a nucleoside 
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analog that impairs DNA synthesis by specifically inhibiting the production process of 
GTP, CDP, and their precursor metabolites. In addition, consistent with recent findings 
for different cancer types (32,45), targeting proline (M00015), and less frequently serine 
(M00020) metabolism, may be efficient strategies for cancer treatment. 
Additional observations may extend the applications of cancer drugs. The predicted 
activation of isoprenoid biosynthesis (M00095) in breast cancer is consistent with a 
potentially protective role of simvastatin in progression of this cancer type (46). 
Following from this observation, predicted metabolic activities support similar 
applications in bladder and endometrial cancer (47). Furthermore, the use of 
pamidronate, which is currently applied to target bone metastasis in breast cancer and 
multiple myeloma, and targets isoprenoid biosynthesis (M00367) module, might also be 
applied to bladder and endometrial cancer (48). It is worth pointing out that other 
bisphosphonates show some benefit in these settings and in colorectal cancer (49), 
which was also predicted in this study. In addition, targeting accumulation of L-
cystathionine (M00035_1) by azacitidine, which causes global DNA hypomethylation, 
may be useful in at least 10 cancer types. The study also supports drug repurposing, like 
the potential use of an approved drug for rheumatoid arthritis, leflunomide (which 
targets UMP biosynthesis) to treat several cancer types (50). Therefore, this study 
describes cancer metabolic dependencies that highlight novel therapeutic opportunities 
either by using current drugs or compounds, or by developing targeted approaches 
against essential gene products.  
It is worth noting that a total of 16 commonly mutated genes from the COSMIC 
database (51) were present in 11 modules. Although it is likely that some of the samples 
used in this study contained any of these mutations, the information about the 
mutational status of the genes in the modules provided in the ICGC repository was 
scarce and so we could not include this information in the model. However, if this 
information were available, two scenarios could be considered by the model used here: 
i) activating mutation (e.g. a translocation to another constitutive promoter), which will 
be detected in the gene expression level itself, and ii) loss-of-function mutation, which 
can be simulated in the model by setting the gene expression value to 0 (an expressed 
non-functional gene is mechanistically equivalent to a non-expressed gene) (52,53).   
Although Project Achilles has yielded abundant data, its results are far from exhaustive 
and, consequently, those obtained here can be considered an underestimate of the actual 
total number of modules that are essential in cancer. 
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Summarizing, changes in metabolic processes play a key role in cancer development 
and progression and this phenomenon is a recognized cancer hallmark (7). However, 
metabolic maps are complex and understanding the global implications in cancer of 
changes in activity of processes or components is challenging. Recently, the metabolic 
map has been decomposed into modules, which consist on sequential reactions 
representing a summary of fundamental metabolic processes (20). Here we have 
explored the usefulness of modules to understand cancer metabolic profiles and their 
relation with cancer outcome and treatment. A simple model is used to predict module 
activity from the expression levels of its gene components.    
In a pan-cancer analysis, we demonstrate that the activity of certain modules change 
significantly between cancers and the corresponding tissues of origin. We also report 
changes in the correlated activity of modules. The activity of several modules is 
significantly associated with cancer prognosis and, moreover, these associations are 
stronger for the module than for any of their constituent genes. This finding strongly 
supports the notion that the effect on the phenotype arises from the coordinated activity 
of the genes in the module. Therefore, essentiality at the gene level would be a 
consequence of the impact of the activity of the corresponding gene product on the 
activity of the module. The associations with outcome and cell viability allow us to coin 
the concepts of tumor suppressor metabolic modules and onco-modules. Finally, using 
this modeling framework, we propose potential therapeutic targets to inhibit metabolic 
reprogramming in cancer.  
Certainly, the metabolic modules used in this modelling framework describe only a 
limited (although representative) portion of the whole known map of human 
metabolism. Therefore, the model presented here provides mechanistic insights into cell 
metabolic activities that are significantly linked to complex phenotypes, such as cancer 
prognosis, but probably has limitations in the accurate prediction of the fate of specific 
metabolites or phenotypes not affected by the metabolites resulting from the 95 
metabolic modules used in the model. More comprehensive models that encompass 
larger portions of the metabolism will, no doubt, increase the reliability of the 
predictions. We anticipate that the data and models produced will play an increasingly 
important role in personalized treatment (54). 
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Figure Legends 
 
Figure 1. Heatmap with the significant (FDR-adjusted p-value <0.05) changes in 
module activity when the 14 cancers analyzed were compared with the corresponding 
tissue of origin. Activity up-regulation is represented in red and downregulation in blue. 
The left-most column represents modules in which one or several gene products are 
targets of cancer drugs; the second column represents modules in which one or several 
gene products are targets of other types of drugs; the third column represents the general 
metabolic categories: carbohydrate (CH), amino acid (AA), lipid (LP) or nucleotide 
(NT). 
 
Figure 2. Changes in correlations of module activities from the normal tissue (inner 
circle) to the corresponding cancer type (outer circle).  The proportion of positive 
correlations in the activity of the modules is represented in red, while the proportion of 
negative correlations is represented in blue. 
 
Figure 3. Correlation between increase in module activity, expressed as log-fold-change 
(X axis) and cell survival (Y axis) corresponding to gene KDs in A) Heparan sulfate 
degradation module and B) Bile acid biosynthesis module.   
 
Figure 4. Graph showing relative cell proliferation upon UPB1 expression depletion 
(two different MISSION shRNAs were used as detailed in the inset) or transduced with 
control vector pLKO.1. The asterisk indicates significant differences (Mann-Whitney 
test p-values < 0.01) and the range of reduction (%) of cell proliferation is also shown. 
The prediction of UPB1 essentiality made by the model in lines AGS and MKN45 
(stomach gastric adenocarcinoma) was confirmed by a relatively more sensitive 
behaviors, while UPB1 does not seem to be relatively sensitive in SW480 (colon 
adenocarcinoma), as predicted by the model as well.  
 
Figure 5. K-M plots showing the relationship between module activity and patient 
survival in different cancer types. High and low module activity groups were defined by 
patients in the 80% and 20% percentiles of module activity, respectively. The X axis 
shows time in months and the number of patients at risk in the high activity and low 
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activity groups. A) Pentose phosphate pathway in LICH; B) C5 isoprenoid biosynthesis 
in LGG; C) Propanoyl-CoA metabolism in KIRC and D) Guanine ribonucleotide 
biosynthesis in KIRP. 
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Table 1. Essential modules. The first column contains the name of the module; the second column the genes knocked down in Project Achilles; the third column lists the other genes in the 
module, whose inhibition is predicted to cause inhibition of the corresponding module and therefore the same effect as the genes in the second column (codes are * confirmed effect, + 
inconclusive effect, - no information available for them); the fourth column states the correlation coefficient (r), whose positive and negative values respectively indicate an onco-module 
and a tumor suppressor module; the fifth column the p-value; the sixth column the cancer tissue from which the cell lines were derived; the seventh column lists the number of different cell 
lines derived from each tissue; the eight column the metabolite class (LP: lipid, CH: carbohydrate, AA: amino acid and NT: nucleotide) and the last column the final metabolite of the 
module.  
Module  KD Genes Predicted KD r p-value Tissue Cell Lines MC Module End Metabolite 
Bile acid biosynthesis AKR1D1 CYP8B1 SLC27A5 
CYP27A1- AMACR- ACOX2* 
CYP7A1 HSD17B4* SCP2- 
HSD3B7* ACOT8* 
-0.883 0.003 Urinary tract 3 LP C00695: Cholic acid 
Dermatan sulfate degradation IDS ARSB HYAL1 
IDUA- HYAL4- SPAM1 HYAL3* 
HYAL2* 
-0.812 0 Bone 6 CH  G00872: Chondroitin 4-sulfate  
C10-C20 isoprenoid biosynthesis IDI1 FDPS GGPS1 IDI2* -0.692 0.016 Stomach 4 LP C00353: Geranylgeranyl diphosphate 
Chondroitin sulfate degradation ARSB HYAL1 HYAL4- SPAM1 HYAL3* HYAL2* -0.662 0.019 Bone 6 CH  G00872: Chondroitin 4-sulfate  
Inosine monophosphate biosynthesis ATIC ADSL PAICS PFAS PPAT GART -0.622 0.035 Prostate 3 NT  C00130: IMP 
Serine biosynthesis PSAT1 PHGDH+ PSPH* -0.61 0.03 Breast 13 AA  C00065: L-Serine 
Leucine degradation DLD BCKDHA IVD BCAT1 
BCKDHB HMGCL HMGCLL1* 
AUH MCCC1 MCCC2* DBT* 
BCAT2 
-0.601 0.043 Urinary tract 3 AA  C00164: Acetoacetate 
beta-Oxidation ACAA1 HADHB EHHADH ECHS1 ACAA2* HADH HADHA -0.58 0 Esophagus 10 LP C02593: Tetradecanoyl-CoA 
Nucleotide sugar biosynthesis PGM1 HK2 HK3 UGP2 PGM2 HK1* HKDC1* -0.552 0.002 Skin 7 CH  C00029: UDP-glucose 
Pentose phosphate pathway (Pentose phosphate 
cycle) 
RPE PGD PGLS 
GPI* TKT* TKTL1* TKTL2* 
RPIA* RPEL1* G6PD* TALDO1 
-0.541 0 Breast 13 CH  C01172: beta-D-Glucose 6-phosphate 
Sphingosine degradation SPHK1 SGPL1 SPHK2* -0.532 0.017 Esophagus 10 LP C00346: Ethanolamine phosphate 
Ceramide biosynthesis 
CERS5 DEGS2 DEGS1 SPTLC1 
SPTLC2 
CERS1* CERS3 CERS6* CERS2 
CERS4* SPTLC3* KDSR* 
-0.523 0.045 Prostate 3 LP C00195: N-Acylsphingosine 
Melatonin biosynthesis AANAT ASMT* DDC* TPH2* TPH1 -0.515 0.044 Pancreas 16 AA  C01598: Melatonin 
Inositol phosphate metabolism ITPK1 IPMK IPPK -0.505 0.025 Kidney 10 LP C01204: Phytic acid 
Glycosphingolipid biosynthesis, ganglio series ST8SIA1 ST3GAL5  -0.5 0 Haematopoietic 27 CH  G00118: Ganglioside (GT3) 
C10-C20 isoprenoid biosynthesis.  IDI1 FDPS GGPS1 IDI2* 0.5 0.022 Skin 7 LP C00353: Geranylgeranyl diphosphate 
Heparan sulfate degradation IDS GNS 
SGSH HPSE2+ IDUA HGSNAT- 
NAGLU* GUSB* 
0.554 0 CNS 35 CH  G02632: glycan  
Pyrimidine degradation DPYD DPYS UPB1* 0.574 0.035 Skin 7 NT  C00099: beta-Alanine 
Pyrimidine degradation DPYD DPYS UPB1* 0.574 0.035 Skin 7 NT  C05145: 3-Aminoisobutyric acid 
Conjugated bile acid biosynthesis SLC27A5 BAAT  0.6 0.006 Kidney 10 LP C05122: Taurocholate 
Conjugated bile acid biosynthesis SLC27A5 BAAT  0.6 0.006 Kidney 10 LP C01921: Glycocholate 
Methionine salvage pathway 
ADI1 MRI1 SRM AMD1 MAT2B 
MAT1A 
APIP+ MTAP* MAT2A* ENOPH1* 0.618 0.032 Soft tissue 2 AA  C00147: Adenine 
Polyamine biosynthesis SRM AMD1 AZIN2* AGMAT* 0.639 0 Haematopoietic 27 AA  C00315: Spermidine 
Nucleotide sugar biosynthesis PGM1 HK2 HK3 UGP2 PGM2* HK1 HKDC1* 0.641 0.025 Urinary tract 3 CH  C00029: UDP-glucose 
Inosine monophosphate biosynthesis ATIC ADSL PAICS PFAS PPAT GART 0.677 0 Bone 6 NT  C00130: IMP 
Dermatan sulfate degradation IDS ARSB HYAL1 
IDUAI* HYAL4- SPAM1* HYAL3 
HYAL2* 
0.692 0 Esophagus 10 CH  G00872: Chondroitin 4-sulfate 
Pyrimidine degradation DPYD DPYS UPB1 0.762 0.037 Stomach 4 NT  C00099: beta-Alanine 
Pyrimidine degradation DPYD DPYS UPB1 0.762 0.037 Stomach 4 NT  C05145: 3-Aminoisobutyric acid 
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